Risedronic acid
生产企业：Warner chilcott co llc, Teva pharmaceuticals usa，另有 1 家
Risedronic acid is a bisphosphonate used to treat osteoporosis and Paget's disease.
Risedronic acid is a bisphosphonate used to treat osteoporosis and Paget's disease.
Risedronatic acid binds to bone hydroxyapatite. Bone resorption causes local acidification, releasing risedronic acid which is that taken into osteoclasts by fluid-phase endocytosis. Endocytic vesicles are acidified, releasing risedronic acid to the cytosol of osteoclasts where they induce apoptosis through inhbition of farnesyl pyrophosphate synthase. Inhibition of osteoclasts results in decreased bone resorption.
Risedronic acid is indicated for the treatment of osteoperosis in men, treatment of Paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosis.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
